45 related articles for article (PubMed ID: 38681439)
1. The curious case of light chain cast nephropathy in a renal allograft recipient.
Choudhury D; Chadha S; Gupta P; Malik M
Indian J Pathol Microbiol; 2024 Jun; ():. PubMed ID: 38847201
[TBL] [Abstract][Full Text] [Related]
2. Bilateral sequential ischemic retinopathy and optic neuropathy in IgG1 heavy chain deposition disease.
Finn MJ; Sharma A; Guenena M; Jiang Y; Savant SV; Ramsey DJ
Eur J Ophthalmol; 2024 May; ():11206721241257553. PubMed ID: 38815990
[TBL] [Abstract][Full Text] [Related]
3. Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis.
Blair HA
Drugs; 2022 Apr; 82(6):683-690. PubMed ID: 35416593
[TBL] [Abstract][Full Text] [Related]
4. Atypical Migration in Serum Immunofixation of Immunoglobulin A with Masked kappa Light Chains: a Case Report and Review of the Literature.
Biaz A; Laamara L; Mahtat E; Bouhsain S; Doghmi K; Dami A; Elmachtani-Idrissi S
Clin Lab; 2023 Apr; 69(4):. PubMed ID: 37057941
[TBL] [Abstract][Full Text] [Related]
5. A Case of μ Heavy and λ Light Chain Amyloidosis in a Patient With Bi-Clonal (IgM κ and λ) Gammopathy Treated With Daratumumab.
Dhaliwal A; Tripathi A; Ravi S
Cureus; 2024 Mar; 16(3):e56994. PubMed ID: 38681439
[TBL] [Abstract][Full Text] [Related]
6. A patient with AL amyloidosis with negative free light chain results.
Milani P; Valentini V; Ferraro G; Basset M; Russo F; Foli A; Palladini G; Merlini G
Clin Chem Lab Med; 2016 Jun; 54(6):1035-7. PubMed ID: 26677890
[TBL] [Abstract][Full Text] [Related]
7. Successful Treatment of Systemic Light Chain Amyloidosis with Liver Involvement using Low-Frequency Daratumumab: A Case Report.
Meng X; He J; Cheng F; Yan H; Zhu C; Guo X; Li Y; Cai Z; He D
Am J Case Rep; 2024 Jan; 25():e942534. PubMed ID: 38229422
[TBL] [Abstract][Full Text] [Related]
8. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine.
Palladini G; Russo P; Bosoni T; Verga L; Sarais G; Lavatelli F; Nuvolone M; Obici L; Casarini S; Donadei S; Albertini R; Righetti G; Marini M; Graziani MS; Melzi D'Eril GV; Moratti R; Merlini G
Clin Chem; 2009 Mar; 55(3):499-504. PubMed ID: 19131635
[TBL] [Abstract][Full Text] [Related]
9. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains.
Katzmann JA; Clark RJ; Abraham RS; Bryant S; Lymp JF; Bradwell AR; Kyle RA
Clin Chem; 2002 Sep; 48(9):1437-44. PubMed ID: 12194920
[TBL] [Abstract][Full Text] [Related]
10. AL amyloidosis with non-amyloid forming monoclonal immunoglobulin deposition; a case mimicking AHL amyloidosis.
Manabe S; Iwasaki C; Hatano M; Kametani F; Yazaki M; Nitta K; Nagata M
BMC Nephrol; 2018 Nov; 19(1):337. PubMed ID: 30466387
[TBL] [Abstract][Full Text] [Related]
11. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
Kastritis E; Palladini G; Minnema MC; Wechalekar AD; Jaccard A; Lee HC; Sanchorawala V; Gibbs S; Mollee P; Venner CP; Lu J; Schönland S; Gatt ME; Suzuki K; Kim K; Cibeira MT; Beksac M; Libby E; Valent J; Hungria V; Wong SW; Rosenzweig M; Bumma N; Huart A; Dimopoulos MA; Bhutani D; Waxman AJ; Goodman SA; Zonder JA; Lam S; Song K; Hansen T; Manier S; Roeloffzen W; Jamroziak K; Kwok F; Shimazaki C; Kim JS; Crusoe E; Ahmadi T; Tran N; Qin X; Vasey SY; Tromp B; Schecter JM; Weiss BM; Zhuang SH; Vermeulen J; Merlini G; Comenzo RL;
N Engl J Med; 2021 Jul; 385(1):46-58. PubMed ID: 34192431
[TBL] [Abstract][Full Text] [Related]
12. How We Manage Systemic Immunoglobulin Heavy Chain Amyloidosis (AH Amyloidosis) and Immunoglobulin Heavy-and-Light-Chain Amyloidosis (AH/AL Amyloidosis).
Chaulagain CP; Herlitz LC; Fu J; Bilani N; Lucitt C; Comenzo RL
Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e826-e831. PubMed ID: 32703752
[No Abstract] [Full Text] [Related]
13. IgM monoclonal gammopathy with heavy-and-light-chain amyloidosis resembling fibrillary glomerulonephritis determined by tandem mass spectrometry: a case report.
Adachi M; Kitamura M; Muta K; Maekawa A; Uramatsu T; Tadokoro M; Funakoshi S; Hisano S; Kuwahara N; Shimizu A; Mukae H; Nishino T
BMC Nephrol; 2020 May; 21(1):195. PubMed ID: 32448180
[TBL] [Abstract][Full Text] [Related]
14. Underlying IgM heavy chain amyloidosis in treatment-refractory IgA nephropathy: A case report.
Wu HT; Wen YB; Ye W; Liu BY; Shen KN; Gao RT; Li MX
World J Clin Cases; 2019 Oct; 7(19):3055-3061. PubMed ID: 31624754
[TBL] [Abstract][Full Text] [Related]
15. The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis.
Nasr SH; Said SM; Valeri AM; Sethi S; Fidler ME; Cornell LD; Gertz MA; Dispenzieri A; Buadi FK; Vrana JA; Theis JD; Dogan A; Leung N
Kidney Int; 2013 Mar; 83(3):463-70. PubMed ID: 23302715
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
